Non-invasive fractional flow reserve tech developer CathWorks said yesterday it won a new CPT code covering its 3D FFRangio non-invasive fractional flow reserve analysis technology.
The Israel-based company’s 3D FFRangio technology is now reimbursable when used for the real-time review of possible atherosclerotic stenosis during coronary angiography interventions.
The FFRangio tech is designed as a non-invasive FFR platform that provides multi-vessel physiologic measurements, CathWorks said.
“CPT code 0523T approval is a very important step for our company and the market. The CPT code decision also reflects the long-term clinical importance of objective FFR-based PCI decision-making. Creating a long-term reimbursement solution to support intraprocedural FFRangio will enable physicians, patients, and payers to realize the proven clinical and economic benefits of FFR on an every-case basis,” CEO Jim Corbett said in a press release.
Last October, CathWorks said it closed a $15.8 million Series B round of financing to support its real-time digital platform designed to determine FFR in cath labs.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.